NF1-dependent disruption of the blood-nerve-barrier is improved by blockade of P2RY14. iScience. 2024; 27:110294.
.Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors. Frontiers in Immunology. 2024; 15:1384623.
.C5aR plus MEK inhibition durably targets the tumor milieu and reveals tumor cell phagocytosis. Life Science Alliance. 2024; 7.
.Schwann cells modulate nociception in neurofibromatosis 1. JCI insight. 2024; 9.
.Shedding New Light: Novel Therapies for Common Disorders in Children with Neurofibromatosis Type I. Pediatric Clinics of North America. 2023; 70:937-950.
.Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis. Clinical Cancer Research. 2023; 29:3744-3758.
.A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation. Blood Advances. 2023; 7:2590-2605.
.Motor Function and Physiology in Youth With Neurofibromatosis Type 1. Pediatric Neurology. 2023; 143:34-43.
.Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of pharmacology and experimental therapeutics. 2023; 385:106-116.
.2023; 21:ia17.
. Abstract IA17: Use of RAS isoforms in nerve tumors. Molecular cancer research : MCR.Runx1/3-driven adaptive endoplasmic reticulum stress pathways contribute to neurofibromagenesis. Oncogene: Including Oncogene Reviews. 2023; 42:1038-1047.
.Merlin tumor suppressor function is regulated by PIP2-mediated dimerization. PloS one. 2023; 18:e0281876.
.Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 2023; 26:106096.
.Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI insight. 2022; 7.
.The Need for New Treatments Targeting MPNST: The Potential of Strategies Combining MEK Inhibitors with Antiangiogenic Agents. Clinical Cancer Research. 2022; 28:3185-3195.
.P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis. eLife. 2022; 11.
.Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST. Cancer Research. 2021; 80:4720-4730.
.Cdc42 activity in Sertoli cells is essential for maintenance of spermatogenesis. Cell Reports. 2021; 37:109885.
.Purinergic signaling in peripheral nervous system glial cells. Glia. 2021; 69:1837-1851.
.WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene: Including Oncogene Reviews. 2021; 40:4229-4241.
.Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current Oncology Reports. 2021; 23:45.
.Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development. Cancers. 2021; 13.
.NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology. 2021; 39:797-806.
.Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer. Science Advances. 2021; 7.
.MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene: Including Oncogene Reviews. 2021; 40:951-963.
.2020; 80:po-043-po-043.
. Abstract PO-043: Plexiform neurofibroma microenvironment at single-cell resolution. Cancer Research.A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genetics in Medicine. 2020; 22:1786-1793.
.Brain-wide structural and functional disruption in mice with oligodendrocyte-specific Nf1 deletion is rescued by inhibition of nitric oxide synthase. Proceedings of the National Academy of Sciences of USA. 2020; 117:22506-22513.
.After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation. Neuro-Oncology Advances. 2020; 2:i23-i32.
.HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. The Journal of Clinical Investigation. 2020; 130:3848-3864.
.Distinct Roles for Rac1 in Sertoli Cell Function during Testicular Development and Spermatogenesis. Cell Reports. 2020; 31:107513.
.Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas. AMERICAN JOURNAL OF CANCER RESEARCH. 2020; 10:856-869.
.The sixth international RASopathies symposium: Precision medicine-From promise to practice. American Journal of Medical Genetics, Part A. 2020; 182:597-606.
.The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies. MOLECULES AND CELLS. 2020; 43:145-152.
.The Role of RUNX1 in NF1-Related Tumors and Blood Disorders. MOLECULES AND CELLS. 2020; 43:153-159.
.NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica. 2020; 139:157-174.
.